Support Centre
31 October 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

New application
Updating record

governing board
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
The influence of two policies of closure of the laparotomy wound in the rate of surgical site infection in colorectal cancer surgery: the New Operation trial
DOI 10.1186/ISRCTN19463413
ClinicalTrials.gov identifier
EudraCT number
Public title The influence of two policies of closure of the laparotomy wound in the rate of surgical site infection in colorectal cancer surgery: the New Operation trial
Scientific title A prospective double blinded randomised multicentre trial of the influence of two policies of closure of the laparotomy wound in the rate of surgical site infection in colorectal cancer surgery
Acronym NewOp
Serial number at source 09/01; PI08/90196
Study hypothesis A decreased faecal load in the surgical wound diminished the incidence of surgical site infection.
Lay summary Not provided at time of registration
Ethics approval The Medical Ethics Committee of the Virgen del Camino Academic Medical Centre, Pamplona gave approval on the 7th May 2009 (ref: 6/2008). Under Spanish law, all other centres will be included under this approval.
Study design Prospective double blinded randomised multicentre trial
Countries of recruitment Spain
Disease/condition/study domain Colorectal cancer
Participants - inclusion criteria 1. Aged above 18 years, either sex
2. Colon and rectal cancer
Participants - exclusion criteria 1. Before the enrolment: emergency surgery
2. At enrolment:
2.1. Not willing to participate
2.2. Non-resectable tumours
2.3. Multi-visceral resection planned
2.4. Recurrence of colon or rectal carcinoma
2.5. Laparoscopic abdominoperineal resection
2.6. Patients programmed to place a mesh simultaneously for an incisional hernia
3. At allocation:
3.1. Non-resectable tumours
3.2. The surgeon decides to prescribe antibiotics due to faecal contamination during operation
3.3. Any violation of the protocol
4. At follow-up:
4.1. Peri-operative mortality
4.2. Patients reoperated for any reason in the first 30 days after primary surgery
4.3. Patients with an organ/space infection draining through the wound
4.4. Patients not followed for at least 30 days after surgery
Anticipated start date 01/06/2009
Anticipated end date 01/06/2011
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 738
Interventions Control group: at the end of the operation the nurses and surgeons will change gloves, a new set of surgical instruments will be used and the surgical drapes surrounding the laparotomy will be changed.

Study group: at the end of the operation and before closing the laparotomy; the surgical assistant will retire all the surgical drapes and the surgeon will retire the plastic coverage of the wound and the wound will be covered with a povidone-soaked gauze. Nurse and surgical teams will scrub again and the surgical instruments will be changed.

Total duration of follow-up: one month after the recruitment of the last patient.
Primary outcome measure(s) Incidence of surgical site infection. The criteria to define surgical site infection are described by Disease Control and Prevention National Healthcare Safety Network (Spain). For the purposes of this study superficial and deep wound infections would be considered as a unique entity condition. This will be measured 30 days after the operation.
Secondary outcome measure(s) The relationship between wound infection rate and the following variables:
1. Age
2. Sex
3. Location of the tumour (colon/rectum)
4. TNM stage
5. Obesity
6. Level of glucose
7. Long course radiotherapy

Measured 30 days after the operation.
Sources of funding Spanish National Research Council (Consejo Superior de Investigaciones Cientificas [CSIC]) (Spain)
Trial website
Publications 1. 2012 results in http://www.ncbi.nlm.nih.gov/pubmed/22430092
Contact name Prof  Hector  Ortiz
  Address Hospital Virgen del Camino
Irunlarrea 4
  City/town Pamplona
  Zip/Postcode 31008
  Country Spain
  Tel +34 65 98 67 210
  Fax +34 94 82 49 942
  Email hortizhu@cfnavarra.es
Sponsor Carlos III Institute of Health (Instituto de Salud Carlos III) (Spain)
  Address C/ Sinesio Delgado 4 - 6 (entrada por Avda. Monforte de Lemos, 5.)
  City/town Madrid
  Zip/Postcode 28029
  Country Spain
  Email Registro.general@isciii.es
  Sponsor website: http://www.isciii.es/htdocs/index.jsp
Date applied 15/05/2009
Last edited 05/04/2012
Date ISRCTN assigned 17/06/2009
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.